Dr. C. Thomas Dow | All Roads Lead from Crohn’s

“All roads lead to Rome” is the old axiom that described the central place the city of Rome played in its millennial world empire.  All roads lead from Crohn’s – this narrative discusses human diseases associated with Mycobacterium avium subsp. paratuberculosis (MAP) other than Crohn’s disease, including Blau syndrome, Type I diabetes, sarcoidosis, lupus and Parkinson’s disease. For our purposes these roads are trails; genetic trails.

Read the Article

The MAP Gap Newsletter | July 2017

Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.

Read all the latest news and research about Mycobacterium avium subsp. paratuberculosis (MAP) and the treatment of Crohn’s and other diseases using Anti-MAP therapy. Enjoy!

Read the Newsletter

The MAP Gap Newsletter | April 2017

Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.

Read all the latest news and research about Mycobacterium avium subsp. paratuberculosis (MAP) and the treatment of Crohn’s and other diseases using AMAT therapy. Enjoy!

Read the Newsletter

Welcome to the Human Paratuberculosis Foundation

The Crohn’s Infection is proud to announce the formation of our new non-profit organization: Human Paratuberculosis Foundation. Human Paratuberculosis Foundation, Inc. is a non-profit organization founded in 2016 under the laws of the State of New York. We are an approved IRS 503(c)(1) charity. In addition, we are happy to let our community know about the 2017 MAP Conference to be held in Philadelphia on March 24-25th. Keep reading for more details and an opportunity to help!

Read the Article

The MAP Gap Newsletter | October 2016

Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.

Read all the latest news and research about Mycobacterium avium subsp. paratuberculosis (MAP) and the treatment of Crohn’s and other diseases using AMAT therapy. Enjoy!

Read the Newsletter

Dr. William Chamberlin | FDA Warning for Fluoroquinolone Antibiotics

Pic Chamberlinby Dr. William Chamberlin

On July 26, 2016, the United States Food and Drug Administration (FDA) issued a warning regarding the use of antibiotics in the fluoroquinolone class. These include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin and gemifloxacin (Factive).

Two of these drugs (levofloxacin and ciprofloxacin) are sometimes prescribed to treat Crohn’s disease via a pathogen model (AMAT). However, the risks associated with the fluoroquinolone class of medications are serious. Because of this, I will no longer recommend the use of levofloxacin or ciprofloxacin for the treatment of Crohn’s disease, except in extreme cases where the benefits may outweigh the serious risks.

Read the Full Article

Prednisone and Prednisolone

Prednisone and Prednisolone are potent immunosupressant, synthetic corticosteroids. They are effectively used to control acute flares in Crohn’s disease. Prednisone works by mimicking the effects of the hormones produced naturally by the adrenal glands to suppress the immune system, but has a much more powerful effect than the naturally occurring hormones. Prednisone suppresses not only the immune response, but the inflammatory products as well.

Read the full article for more information on prednisone and prednisolone, including the difference between prednisone vs. prednisolone, prednisone dependence, side effects, and the potential affect on Mycobacterium avium spp. paratuberculosis (MAP). 

Read the Full Article

Dr. Michael Collins | 2016 World Buiatrics Congress Keynote Address

Michael CollinsVeterinary medicine and animal agriculture had our chance to deal with paratuberculosis before it became an epidemic. Today, 121 years since Heinrich Albert Johne described paratuberculosis in a Guernsey cow in Germany, well over half of all dairy herds in virtually all major dairy-producing countries are infected with M. paratuberculosis. It is almost certain that humans are becoming infected and that the most probable means of infection is via the food supply.

Read more about the facts, predictions and what can be done to control M. paratuberculosis in Dr. Michael T. Collins’ 2016 World Buiatrics Congress Keynote Address.

Read the Full Article

The MAP Gap Newsletter | July 2016

TCI BannerThe Crohns Infection is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.

Here are some of the most recent developments in the area of MAP related Crohn’s Research. Enjoy!

Read the Newsletter

Pin It on Pinterest

Share This